Out-of-Season Epidemic of Respiratory Syncytial Virus during the COVID-19 Pandemic: The High Burden of Child Hospitalization in an Academic Hospital in Southern Italy in 2021

Daniela Loconsole 1,*, Francesca Centrone 1,*, Caterina Rizzo 2,*, Désirée Caselli 3,*, Azzurra Orlandi 3,*, Fabio Cardinale 4, Cristina Serio 4, Paola Giordano 5, Giuseppe Lassandro 5, Leonardo Milella 6,*, Maria Teresa Ficarella 6,*, Maria Elisabetta Baldassarre 7,*, Nicola Laforgia 8,*, and Maria Chironna 1,*,*

Abstract: Respiratory syncytial virus (RSV) infection is the most common cause of hospitalization in young children. In the last 2 years, public health measures aimed at controlling the spread of SARS-CoV-2 have affected the epidemiology and seasonality of RSV worldwide. The aim of this descriptive retrospective observational study was to describe the characteristics of children hospitalized with RSV in an academic tertiary care hospital in Southern Italy in 2021. We also investigate the seasonal trends of RSV from 2017 to 2021. The demographic characteristics, comorbidities, clinical data, and coinfections were retrospectively evaluated. Compared with previous seasons, the 2021 outbreak of RSV was characterized by an increased number of patients, with a delayed peak observed in November. Overall, 179 children, including 128 (71.5%) aged <12 months, were hospitalized for RSV infection between August and December 2021. Ten children (5.6%) were admitted to the intensive care unit (ICU), all aged <5 months. One patient (0.5%) aged <1 month with severe comorbidities died. The severity of symptoms was significantly associated with younger age, underlying chronic disease, and the length of hospital stay (p < 0.05 each). History of prematurity was not significantly associated with the presence of coinfections. Because of the high burden of RSV infection and the expected larger RSV epidemics resulting from a greater number of RSV-naïve children, systematic epidemiological and virological surveillance is needed. Appropriate pathways for access to RSV prevention in all infants should also be introduced.

Keywords: respiratory syncytial virus (RSV); bronchiolitis; epidemiology; COVID-19; children; hospitalization; prevention
1. Introduction

Respiratory syncytial virus (RSV) is the leading cause of respiratory infection in young children [1–3]. In particular, RSV infection is the leading cause of both death and hospitalization for respiratory illnesses in children aged <1 year [4,5]. More than 60% of children are infected with RSV during the first year of life and almost all are infected before the age of 2 years [6,7]. It has been estimated that 58,000 children aged <5 years are hospitalized annually due to RSV infection in the United States [6]. Overall, RSV is responsible for 5% of deaths worldwide among children aged <5 years, with most RSV-related deaths occurring in infants during the first year of life [8,9].

The seasonal pattern of RSV infection depends on geographic location and climate. In temperate regions of the Northern Hemisphere, RSV typically peaks in the winter months every year [4,10]. In Italy, the annual outbreak usually occurs from late fall to early spring, peaking in January–February [10,11]. Both subtypes of RSV (A and B) co-circulate during annual outbreaks, although one subtype usually predominates each year. The A subtype seems to correlate with a more severe infection [12].

RSV infection causes a wide range of symptoms including upper and lower respiratory tract infections, the latter including bronchiolitis and pneumonia. Bronchiolitis often occurs after the onset of rhinitis and is associated with cough, dyspnea, and wheezing, especially in neonates and infants [13,14]. In younger children, RSV infection can also be characterized by fever, feeding difficulties, and irritability [13]. The main risk factor for RSV infection and hospitalization is being aged between birth and <1 year just before or during an outbreak. Living with siblings, a low birth weight, exposure to cigarette smoke, and lack of breastfeeding increase the risk of severe infection [15]. Severe outcomes and death occur more frequently in preterm infants and infants with congenital heart disease, chronic lung disease, or immunodeficiency syndromes [9]. The economic burden of RSV infections is notable, especially considering the cost of hospitalizations, admission to intensive care units, and length of stay [16].

At present, no national guidelines have approved specific treatments for RSV infections [17]. Severe forms of bronchiolitis may require oxygen administration, non-invasive or invasive ventilation, and hydration or parenteral nutrition [17]. Because of the lack of effective therapies, a reduction in morbidity and mortality from RSV must rely on preventive measures. Prophylaxis with monthly injections of the monoclonal antibody palivizumab to reduce RSV infection is available for children born at a gestational age ≤35 weeks, for children aged <6 months at the beginning of the RSV season and for children aged <2 years with major risk factors [18,19].

In the last 2 years, public health measures aimed at controlling the spread of SARS-CoV-2, such as stay-at-home orders and social distancing, have altered the epidemiology and seasonality of other respiratory viruses [20,21]. Some studies showed a drastic reduction in the number of hospitalizations and a reduction in the length of hospital stay in children with respiratory diseases [22,23]. Moreover, a drop in the total number of pediatric consultations was reported during the 2020 lockdown both in Italy and in Finland [24,25].

It has been reported that the rate of RSV infection decreased markedly in Europe during the pandemic, decreasing from a peak of 2000–2500 cases per week during previous seasonal outbreaks in 2016–2020 to fewer than 700 cases per week in 2020–2021 [26]. In France, the rate of bronchiolitis-correlated hospitalizations decreased by 82.5% and in Belgium, the number of RSV cases in 2020 decreased by 99% compared with the previous three seasons [27–29]. Also in Finland, a rapid decrease in RSV cases was observed in 2020 [25]. A study conducted in Spain during the pandemic period revealed a very low burden of bronchiolitis, mostly caused by RSV, and a delayed peak compared with previous years [22]. In Italy, systematic national surveillance of RSV is lacking, therefore very few epidemiological data are available. Some studies have been performed using samples collected for influenza surveillance based on the definition of influenza-like illnesses [12,30]. These studies showed that RSV infection in Italy had almost completely disappeared in children during the 2020–2021 season [30–32]. In particular, the rate of acute bronchioli-
RSV was reported to be 84–95% lower in the 2020–2021 season compared with previous seasons [32,33]. In 2021, however, an interseasonal resurgence of RSV was observed in many countries. The aim of the study was to describe the clinical and epidemiological characteristics of children hospitalized for RSV in an academic tertiary care hospital in Southern Italy during the out-seasonal outbreak in 2021. We also investigated the seasonal trends of hospitalized RSV-positive cases, analyzing data on RSV hospitalizations from 2017 to 2021.

2. Materials and Methods

This descriptive observational study evaluated children hospitalized for RSV infection in the Policlinico-Giovanni XXIII Hospital of Bari (Italy), a tertiary care hospital in Southern Italy that covers a population of about 158,716 children and has 208 pediatric beds. All pediatric patients hospitalized with a positive real-time PCR test for RSV between 1 January 2017 and 31 December 2021 were considered for the construction of the epidemic curves. Pediatric patients hospitalized with RSV infection between 1 August 2021 and 31 December 2021 were analyzed in-depth using a retrospective collection of their demographic and clinical characteristics, comorbidities, and coinfections.

Nasopharyngeal swabs and/or aspirates were collected in the ward at the time of hospitalization and sent to the Laboratory of Molecular Epidemiology and Public Health of the Hygiene Unit of Policlinico Hospital. Samples were processed immediately or after storage at −80 °C. Nucleic acids were extracted using the STARMag Universal Cartridge Kit (Seegene, Korea) on the automated Nimbus IV platform. Real-time PCR was performed using the AllplexTM Respiratory Panel Assays (Seegene, Korea) to detect 16 different viruses, including influenza A and B viruses, RSV A and B, adenovirus, enterovirus, parainfluenza viruses 1–4, metapneumovirus, bocavirus, rhinovirus, and three coronaviruses, NL63, 229E, and OC43. Samples were also analyzed using AllplexTM SARS-CoV-2 Assays (Seegene, Korea) to detect SARS-CoV-2.

For analytic purposes, the need for oxygen support was considered a criterion for severe symptoms. Statistical analyses were performed with STATA 12.0 software (StataCorp LLC, College Station, TX 77845-4512, USA). Proportions were compared by chi-squared tests, with \( p \) values ≤ 0.05 considered statistically significant. A multivariate logistic regression model was used to explore associations between severity of clinical signs and age, sex, comorbidities, coinfections, subtype of RSV, history of prematurity, and length of hospital stay.

All procedures performed in the study were in accordance with the ethical standards of the institutional and national research committees, and the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Ethical approval was obtained from the Institutional Review Board at the Apulian Regional Observatory for Epidemiology (n. 614 | 04 of 4 January 2022), which waived the requirement for informed consent because all data were deidentified.

3. Results

Between 1 January 2017 and 31 December 2021, 1082 children were hospitalized for RSV infection. The average number of admissions per year was 216. The 2021 outbreak differed significantly from previous years, as no cases were registered until August 2021 (Figure 1).
Compared with previous seasons, in which hospitalizations peaked during February, the 2021 outbreak began much later in the year and peaked in November. Between August and December 2021, 179 children were hospitalized for RSV infection, including 136 (76%) infected with RSV B, 41 (23%) infected with RSV A, and two (1%) with both. The demographic and clinical characteristics of these patients are summarized in Table 1.

Table 1. Demographic and clinical data of children hospitalized for RSV infection in 2021.

|                          | N   | %    |
|--------------------------|-----|------|
| **Total**                | 179 |      |
| **Age groups (months)**  |     |      |
| 0–12                     | 128 | 71.5%|
| 13–24                    | 15  | 8.4% |
| >24                      | 36  | 20.1%|
| **Sex**                  |     |      |
| Male                     | 94  | 52.5%|
| Female                   | 85  | 47.5%|
| **Symptoms**             |     |      |
| Fever                    | 89  | 49.7%|
| Dyspnea                  | 133 | 74.3%|
| Wheezing                 | 60  | 33.5%|
| Cough                    | 155 | 86.6%|
| Rhinitis                 | 103 | 57.5%|
| Feeding difficulties     | 83  | 46.4%|
| **Comorbidity**          | 38  | 21.2%|
| **Prematurity at birth** | 32  | 17.9%|
| Days from symptom onset to hospitalization average (range) | 4.2 (0–45) |
| Length of hospital stay (days) average (range) | 5.8 (1–16) |

The median age of these 179 children was 4 months (IQR, 1–18 months), with 128 (71.5%) aged <12 months. Eighty-eight children (49.2%) required oxygen support. The average length of hospital stay was 5.8 days (range, 1–16 days). Of the hospitalized children born in 2021, 46.8% were born in September or October. Ten (5.6%) of the 179 hospitalized children were admitted to the intensive care unit (ICU), all of whom were aged <5 months. One patient (0.5%) aged <1 month with severe comorbidities died. Of the 179 children, 67 (37.4%) were coinfected with an additional virus, including six (9%) who were positive for SARS-CoV-2, 32 (47.8%) infected with rhinovirus, 18 (26.9%) infected with bocavirus, 12 (17.9%) infected with adenovirus, and 12 (17.9%) infected with other viruses.
Based on the criteria for the administration of palivizumab, 21 patients were eligible for prophylaxis. Of these, nine children (42.9%) received at least one dose of palivizumab.

Table 2 shows a comparison between the demographic and clinical characteristics of the patients by age group.

Table 2. Comparison of demographic and clinical data of children hospitalized for RSV infection by age group.

| Age Groups | 0–12 Months N (%) | 13–24 Months N (%) | >24 Months N (%) | p-Value |
|------------|-------------------|--------------------|-----------------|---------|
| Total      | 128               | 15                 | 36              |         |
| Sex        |                   |                    |                 |         |
| Male       | 64 (50.0%)        | 9 (60.0%)          | 21 (58.3%)      | 0.56    |
| Female     | 64 (50.0%)        | 6 (40.0%)          | 15 (41.7%)      |         |
| Symptoms   |                   |                    |                 | <0.00001|
| Fever      | 49 (38.3%)        | 11 (73.3%)         | 29 (80.6%)      |         |
| Dyspnea    | 112 (87.5%)       | 6 (40.0%)          | 15 (41.7%)      | <0.00001|
| Wheezing   | 42 (32.8%)        | 7 (46.7%)          | 11 (30.6%)      | 0.51    |
| Cough      | 117 (91.4%)       | 13 (86.7%)         | 25 (69.4%)      | 0.003   |
| Rhinitis   | 79 (61.7%)        | 7 (46.7%)          | 17 (47.2%)      | 0.20    |
| Feeding difficulties | 63 (49.2%) | 6 (40.0%) | 14 (38.9%) | 0.48 |
| Comorbidity| 22 (17.2%)        | 3 (20.0%)          | 13 (36.1%)      | 0.049   |
| Prematurity at birth | 25 (19.5%) | 2 (15.4%) | 5 (14.3%) | 0.66 |

Children aged 0–12 months were more likely to show dyspnea ($p < 0.0001$) and cough ($p = 0.003$), whereas older children were more likely to show fever ($p < 0.0001$). Multivariate logistic regression showed that the severity of symptoms was significantly associated with younger age (OR: 0.94, 95% CI, 0.91–0.96), underlying chronic disease (OR: 5.39, 95% CI, 1.7–17.1), and the length of hospital stay (OR: 1.25, 95% CI, 1.1–1.4). Symptom severity was not significantly associated with a history of prematurity, the presence of coinfections, or the subtype of RSV.

4. Discussion

The 2021 RSV season did not occur during the expected time of the year, with the present study showing that the first pediatric patient was admitted to hospital for RSV infection in August 2021. Hospitalizations for RSV peaked in November 2021, later than in previous seasons, and were characterized by an increased number of cases. Worldwide, the seasonal pattern of RSV outbreaks was disrupted by the SARS-CoV-2 outbreak and the non-pharmaceutical interventions (NPIs) introduced to contain the spread of the latter virus [34]. During the study period, a low circulation of SARS-CoV-2 was registered in the Apulia region until the beginning of the so-called “fourth wave” in late December 2021 [35]. The average incidence of SARS-CoV-2 infection was 35.9/100,000 inhabitants, ranging from 16.7 to 63.1/100,000 [35]. Social distancing, the use of masks in indoor settings irrespective of vaccination status, and the use of a sanitary passport (vaccination or periodic SARS-CoV-2 testing) were the main public health measures applied to contain the spread of SARS-CoV-2 [36].

In Finland, a rapid decrease in the number of RSV cases in the nationwide lockdown period compared with previous seasons was observed [25]. Also in Spain, during the winter of 2020–2021, a reduction in the rate of RSV diagnoses of 44.3% per thousand inhabitants less than 2 years of age and the rate of RSV admissions of 1.4% per thousand was reported [37]. In addition, a delayed peak of RSV infections was recorded in France during the 2020–2021 season [38]. In particular, the highest number of RSV infections was registered 10–12 weeks after the seasonal peak of previous seasons [38].
Mathematical models have forecast large RSV outbreaks in the next few years due to a buildup of susceptible children [34,39]. In 2021, Australia experienced an interseasonal resurgence of RSV infections with a peak during the austral summer, and the USA also experienced an unusual increase in RSV cases during the spring and summer of 2021 [40–42]. Hospital admissions during the Australian interseasonal peak of 2021 included a higher percentage of older children than during previous seasons [40]. In particular, the numbers of hospitalized children aged 12–24 months and 24–48 months were 6.2-fold and 3.4-fold higher, respectively, in 2021 than during previous years [40]. These findings support the hypothesis that higher percentages of older children were RSV-naïve due to SARS-CoV-2 public health measures. Unexpectedly, the present study found that most hospitalized children were aged <12 months, despite the delayed peak of RSV infection. This finding may be due to younger children with the most severe cases being preferentially admitted to a tertiary care hospital.

Most children hospitalized for RSV infection are healthy infants born at term [43]. The present study also found that more than 80% of the hospitalized children were born at term and that a history of prematurity was not associated with a more severe form of infection. Moreover, despite underlying chronic conditions being associated with the severity of symptoms, only 20% of the children in this study showed comorbidities. The month of birth has also been reported to be a risk factor for RSV infection [44]. Similarly, this study found that about 50% of the hospitalized children born in 2021 were born in September or October, at the beginning of the RSV epidemic. The length of hospital stay in the present study was nearly 6 days, longer than the 4.4 days reported in Spain and the 2.1 days reported in Australia [40,45]. The extended length of stay in the present study may be due to the younger age of the children hospitalized in Italy.

The present study also found that younger children were more likely to show dyspnea and cough, whereas older children were more likely to show fever. Overall, 5.6% of patients were admitted to the pediatric ICU, a percentage similar to that reported in Spain in 2018 [44]. In the latter study, being aged <2 months and having other underlying chronic conditions were the main risk factors associated with admission to the ICU [44]. In comparison, all patients in the present study admitted to the ICU were aged <5 months and the majority had comorbidities. The death rate among hospitalized children in the present study was 0.5%, similar to the 0.3% reported in Spain [44].

During the COVID-19 pandemic in the 2020–2021 season, rhinovirus was reported to be primarily responsible for acute respiratory syndrome and hospitalizations for bronchiolitis [31,33,45]. This non-enveloped virus is less affected by NPIs, such as handwashing and the use of ethanol-containing disinfectants [46,47]. Interestingly, the present study found that 47.8% of the reported coinfections were caused by rhinovirus, confirming its high circulation during the COVID-19 pandemic.

The community burden of RSV infection in Italy remains underestimated as a systematic surveillance system for RSV infection has not yet been introduced. Clinical manifestations of RSV in children aged <5 years may persist for 14 days after onset, suggesting the need to consider the persistence of these manifestations when evaluating the clinical and socio-economic burden of RSV infections in young children in primary care [48]. Only 3% of RSV-infected children in primary care showed comorbidity, and 5% were born prematurely, suggesting that the majority of infected children were otherwise healthy [48]. Determining the estimated direct and indirect costs of RSV infections should lead to an in-depth evaluation of the possible benefits of extending antibody prophylaxis to all children. Fewer than 50% of eligible children in the present study received RSV prophylaxis, suggesting the need for wider access to palivizumab. However, the unexpected out-of-season outbreak of RSV in 2021 could have affected the administration of palivizumab in the correct time frame. The high burden reported for RSV infections suggests that targeting all children for preventive measures would be a more effective strategy [16]. Moreover, RSV circulation should be monitored in the coming months to better manage the infections and the prophylaxis.
To date, no specific vaccines have been approved to prevent RSV, although their development is among the priorities of the World Health Organization [49]. Two approaches have been suggested for immunization against RSV: maternal immunization for children aged <6 months and pediatric vaccines for children aged >6 months. Maternal immunization during the third trimester of pregnancy could increase the amount of anti-RSV antibodies passed from the mother to the infant. The passive immunization of infants using this strategy is advisable, as any RSV vaccine in infants would not protect them from infection during the first weeks of life when the risk of hospitalization for RSV is higher [11,41].

5. Conclusions

Although the RSV 2021 season was delayed in many countries, Southern Italy experienced an out-of-season RSV epidemic, beginning in August and peaking in November 2021. Because of public health measures imposed to prevent the further spread of SARS-CoV-2, larger RSV epidemics are expected over the next few years due to an increase in RSV-naive children. The community burden of RSV infection is still unclear. A systemic national and regional epidemiological and virological surveillance system is needed in Italy. Moreover, to limit the clinical and socio-economic burdens, methods are needed to provide all infants with access to anti-RSV antibodies.

Author Contributions: Conceptualization, D.L., M.E.B. and M.C.; methodology, F.C. (Francesca Centrone) and D.L.; formal analysis, F.C. (Francesca Centrone); investigation, D.C., F.C. (Fabio Cardinale), P.G., L.M. and N.L.; data curation, A.O., C.S., G.L., M.T.F. and M.E.B.; writing—original draft preparation, D.L. and F.C. (Francesca Centrone); writing—review and editing, D.C., C.R., F.C. (Fabio Cardinale), P.G., L.M., M.E.B., N.L. and M.C. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: All procedures performed in the study were in accordance with the ethical standards of the institutional and national research committees, and the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Ethical approval was obtained from the Institutional Review Board at the Apulian Regional Observatory for Epidemiology (n. 614|04 of 4 January 2022), which waived the requirement for informed consent because all data were deidentified.

Informed Consent Statement: Patient consent was waived due to de-identification of all data.

Data Availability Statement: Data are available on request from the corresponding author.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Shi, T.; McAllister, D.A.; O’Brien, K.L.; Simoes, E.A.F.; Madhi, S.A.; Gessner, B.D.; Polack, F.P.; Balsells, E.; Acacio, S.; Aguayo, C.; et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: A systematic review and modelling study. *Lancet* 2017, 390, 946–958. [CrossRef]
2. Bont, L.; Checchia, P.A.; Fauroux, B.; Figueras-Aloy, J.; Manzoni, P.; Paes, B.; Simões, E.A.; Carbonell-Estrany, X. Defining the epidemiology and burden of severe respiratory syncytial virus infection among infants and children in western countries. *Infect. Dis. Ther.* 2016, 5, 271–298. [CrossRef] [PubMed]
3. Hall, C.B.; Weinberg, G.A.; Ivane, M.K.; Blumkin, A.K.; Edwards, K.M.; Staat, M.A.; Auinger, P.; Griffin, M.R.; Poehling, K.A.; Erdman, D.; et al. The burden of respiratory syncytial virus infection in young children. *N. Engl. J. Med.* 2009, 360, 588–598. [CrossRef] [PubMed]
4. Janet, S.; Broad, J.; Snape, M.D. Respiratory syncytial virus seasonality and its implications on prevention strategies. *Hum. Vaccines Immunother.* 2018, 14, 234–244. [CrossRef] [PubMed]
5. Mazur, N.I.; Martinón-Torres, F.; Baraldi, E.; Fauroux, B.; Greenough, A.; Heikkinen, T.; Manzoni, P.; Mejias, A.; Nair, H.; Papadopoulos, N.G.; et al. Lower respiratory tract infection caused by respiratory syncytial virus: Current management and new therapeutics. *Lancet Respir. Med.* 2015, 3, 888–900. [CrossRef]
6. Centers for Disease Control and Prevention. RSV in Infants and Young Children. Available online: https://www.cdc.gov/rsv/high-risk/infants-young-children.html (accessed on 7 February 2022).
7. Stein, R.T.; Bont, L.J.; Zar, H.; Polack, F.P.; Park, C.; Claxton, A.; Borok, G.; Butykova, Y.; Wegzyn, C. Respiratory syncytial virus hospitalization and mortality: Systematic review and meta-analysis. Pediatr. Pulmonol. 2017, 52, 556–569. [CrossRef]

8. GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: A systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016, 388, 1545–1606. [CrossRef]

9. Scheltema, N.M.; Gentile, A.; Lucion, F.; Nokes, D.J.; Munywoki, P.K.; Madhi, S.A.; Groome, M.J.; Cohen, C.; Moyes, J.; Thorburn, K.; et al. Global respiratory syncytial virus-associated mortality in young children (RSV GOLD): A retrospective case series. Lancet Glob. Health 2017, 5, e984–e991. [CrossRef]

10. Obando-Pacheco, P.; Justicia-Grande, A.J.; Rivero-Calle, I.; Rodríguez-Tenreiro, C.; Sly, P.; Ramilo, O.; Mejías, A.; Baraldi, E.; Papadopoulos, N.G.; Nair, H.; et al. Respiratory syncytial virus seasonality: A global overview. J. Infect. Dis. 2018, 217, 1336–1346. [CrossRef]

11. Bozzola, E. Respiratory syncytial virus resurgence in Italy: The need to protect all neonates and young infants. Int. J. Environ. Res. Public Health 2021, 19, 380. [CrossRef]

12. Azzari, C.; Baraldi, E.; Bonanni, P.; Bozzola, E.; Coscia, A.; Lanari, M.; Manzoni, P.; Mazzone, T.; Sandri, F.; Checcucci Lisi, G.; et al. Epidemiology and prevention of respiratory syncytial virus infections in children in Italy. Ital. J. Pediatr. 2021, 47, 198. [CrossRef] [PubMed]

13. Barr, R.; Green, C.A.; Sande, C.J.; Drysdale, S.B. Respiratory syncytial virus: Diagnosis, prevention and management. Ther. Adv. Infect. Dis. 2019, 6, 204993611985798. [CrossRef] [PubMed]

14. Takeyama, A.; Hashimoto, K.; Sato, M.; Sato, T.; Tomita, Y.; Maeda, R.; Ito, M.; Katayose, M.; Kawasaki, Y.; Hosoya, M. Clinical and epidemiologic factors related to subsequent wheezing after virus-induced lower respiratory tract infections in hospitalized pediatric patients younger than 3 years. Eur. J. Pediatr. 2014, 173, 959–966. [CrossRef] [PubMed]

15. Lanari, M.; Pinelli, F.; Adorni, F.; Di Santo, S.; Vandini, S.; Silvestri, M.; Muscico, M.; Study Group of Italian Society of Neonatology on Risk Factors for RSV Hospitalization. Risk factors for bronchiolitis hospitalization during the first year of life in a multicenter Italian birth cohort. Ital. J. Pediatr. 2015, 41, 40. [CrossRef]

16. Bozzola, E.; Ciarlito, C.; Guolo, S.; Brusco, C.; Cerone, G.; Antilici, L.; Schettini, L.; Piscitelli, A.; Chiara Vittucci, A.; Cutrera, R.; et al. Respiratory syncytial virus bronchiolitis in infancy: The acute hospitalization cost. Front. Pediatr. 2021, 9, 594898. [CrossRef]

17. Ralston, S.L.; Lieberthal, A.S.; Meissner, H.C.; Alverson, B.K.; Baley, J.E.; Gadomski, A.M.; Johnson, D.W.; Light, M.J.; Maraqa, N.F.; Mendonca, E.A.; et al. Clinical practice guideline: The diagnosis, management, and prevention of bronchiolitis. Pediatrics 2014, 134, e1474–e1502. [CrossRef]

18. Agenzia Italiana del Farmaco. Determina 2 Novembre 2017. Available online: https://www.gazzettaufficiale.it/eli/id/2017/11/09/17A07585/sg.2017 (accessed on 15 February 2022).

19. Bollani, L.; Baraldi, E.; Chirico, G.; Dotta, A.; Lanari, M.; Del Vecchio, A.; Manzoni, P.; Boldrini, A.; Paolillo, P.; Di Fabio, S.; et al. Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV). Ital. J. Pediatr. 2015, 41, 97. [CrossRef]

20. Tan, J.Y.; Conceicao, E.P.; Sim, X.Y.J.; Wee, L.E.I.; Aung, M.K.; Venkatachalam, I. Public health measures during COVID-19 pandemic reduced hospital admissions for community respiratory viral infections. J. Hosp. Infect. 2020, 106, 387–389. [CrossRef]

21. Lassandro, G.; Palladino, V.; Amoruso, A.; Palmieri, V.V.; Russo, G.; Giordano, P. Children in coronaviruses’ wonderland: What clinicians need to know. Mediterr. J. Hematol. Infect. Dis. 2020, 12, e2020042. [CrossRef]

22. Guitart, C.; Bobillo-Perez, S.; Alejandre, C.; Armesto, G.; Canaves, C.; Cambra, F.J.; Balague, M.; Jordan, I.; Hospital Network for R. S. V. Surveillance in Catalonia. Bronchiolitis, epidemiological changes during the SARS-CoV-2 pandemic. BMC Infect. Dis. 2022, 22, 84. [CrossRef]

23. Nascimento, M.S.; Baggio, D.M.; Fascina, L.P.; do Prado, C. Impact of COVID-19 on the seasonality of pediatric respiratory diseases. PLoS ONE 2020, 15, e0243694. [CrossRef] [PubMed]

24. Brisa, G.; Vagelli, G.; Tagliarini, G.; Rotulo, A.; Pirlo, D.; Romanengo, M.; Piccotti, E. The impact of COVID-19 lockdown on children with medical complexity in pediatric emergency department. Am. J. Emerg. Med. 2021, 42, 225–227. [CrossRef] [PubMed]

25. Kuitunen, I.; Artama, M.; Mäkelä, L.; Backman, K.; Heiskanen-Kosma, T.; Renko, M. Effect of Social Distancing Due to the COVID-19 Pandemic on the Incidence of Viral Respiratory Tract Infections in Children in Finland During Early 2020. Pediatr. Infect. Dis. J. 2020, 39, e423–e427. [CrossRef] [PubMed]

26. European Centre for Disease Control and Prevention. Surveillance Atlas of Infectious Diseases. Available online: https://atlas.ecdc.europa.eu/public/index.aspx (accessed on 31 July 2021).

27. Guedj, R.; Lorrot, M.; Lecarpentier, T.; Leger, P.L.; Corvol, H.; Carbayal, R. Infant bronchiolitis dramatically reduced during the second French COVID-19 outbreak. Acta Paediatr. 2021, 110, 1297–1299. [CrossRef] [PubMed]

28. Ramhoud, J.; Dauget, S.; Morin, L.; Bergounioux, J.; Leger, P.L.; Carbayal, R.; Renolleau, S.; Guedj, R. Bronchiolitis admissions to intensive care during COVID-19. Pediatrics 2021, 147, e2021051013. [CrossRef] [PubMed]

29. Van Brusselen, D.; De Troeyer, K.; Ter Haar, E.; Vander Auwera, A.; Poschet, K.; Van Nuijs, S.; Bael, A.; Stobbeelaar, K.; Verhulst, S.; Van Herendael, B.; et al. Bronchiolitis in COVID-19 times: A nearly absent disease? Eur. J. Pediatr. 2021, 180, 1969–1973. [CrossRef]

30. Pellegrinelli, L.; Galli, C.; Bubba, L.; Seiti, A.; Anselmi, G.; Primache, V.; Signorini, L.; Delbue, S.; Bindia, S.; Pariani, E. Respiratory syncytial virus in pediatric influenza-like illness cases in Lombardy, Northern Italy, during seven consecutive winter seasons (from 2014 to 2020–2021). Influenza Other Respir. Viruses 2022, 16, 481–491. [CrossRef]
31. Vittucci, A.C.; Piccioni, L.; Coltella, L.; Carlitto, C.; Antilici, L.; Bozzola, E.; Midulla, F.; Palma, P.; Perno, C.F.; Villani, A. The disappearance of respiratory viruses in children during the COVID-19 pandemic. Int. J. Environ. Res. Public Health 2021, 18, 9550. [CrossRef]

32. Curatola, A.; Lazzareschi, I.; Bersani, G.; Covino, M.; Gatto, A.; Chiaretti, A. Impact of COVID-19 outbreak in acute bronchiolitis: Lesson from a tertiary Italian Emergency Department. Pediatr. Pulmonol. 2021, 56, 2484–2488. [CrossRef]

33. Ghirardo, S.; Ullmann, N.; Ciofi Degli Atti, M.L.; Raponi, M.; Cutrera, R. Delayed season’s onset and reduction of incidence of bronchiolitis during COVID-19 pandemic. Pediatr. Pulmonol. 2021, 56, 2780–2781. [CrossRef]

34. Baker, R.E.; Park, S.W.; Yang, W.; Vecchi, G.A.; Metcalf, C.E.; Grenfell, B.T. The impact of COVID-19 nonpharmaceutical interventions on the future dynamics of endemic infections. Proc. Natl. Acad. Sci. USA 2020, 117, 30547–30553. [CrossRef] [PubMed]

35. Scienza in Rete. La Progressione Dell’epidemia Covid in Italia e Nelle Regioni per Classi di Età. Available online: https://www.scienzainrete.it/dashboard-eta/ (accessed on 28 March 2022).

36. Disposizioni Attuative Dell’articolo 9, Comma 10, del Decreto-Legge 22 Aprile 2021, n. 52, Recante «Misure Urgenti per la Graduale Ripresa delle Attivita’ Economiche e Sociali nel Rispetto delle Esigenze di Contenimento della Diffusione Dell’epidemia da COVID-19». (21A03739). Available online: https://www.trovanorme.salute.gov.it/norme/dettaglioAtto?id=81157 (accessed on 28 March 2022).

37. Reyes Dominguez, A.I.; Pavlovic Nestic, S.; Urquia Martí, L.; Pérez González, M.D.C.; Reyes Suárez, D.; García-Muñoz Rodrigo, F. Effects of public health measures during the SARS-CoV-2 pandemic on the winter respiratory syncytial virus epidemic: An interrupted time series analysis. Paediatr. Perinat. Epidemiol. 2022, 36, 329–336. [CrossRef] [PubMed]

38. Delestrain, C.; Danis, K.; Hau, I.; Behillil, S.; Billard, M.N.; Krajten, L.; Cohen, R.; Bont, L.; Épaud, R. Impact of COVID-19 social distancing on viral infection in France: A delayed outbreak of RSV. Pediatr. Pulmonol. 2021, 56, 3669–3673. [CrossRef] [PubMed]

39. Zheng, Z.; Pitzer, V.E.; Shapiro, E.D.; Bont, L.J.; Weinberger, D.M. Estimation of the timing and intensity of reemergence of respiratory syncytial virus following the COVID-19 pandemic in the US. JAMA Netw. Open 2021, 4, e2141779. [CrossRef] [PubMed]

40. Foley, D.A.; Phuong, L.K.; Peplinski, J.; Lim, S.M.; Lee, W.H.; Farhat, A.; Minney-Smith, C.A.; Martin, A.C.; Mace, A.O.; Sikazwe, C.T.; et al. Examining the interseasonal resurgence of respiratory syncytial virus in Western Australia. Arch. Dis. Child. 2022, 107, e7. [CrossRef] [PubMed]

41. Centers for Disease Control and Prevention. SV National Trends. Available online: https://www.cdc.gov/surveillance/nrevss/rsv/natl-trend.html (accessed on 30 January 2021).

42. Zheng, Z.; Warren, J.L.; Artin, I.; Pitzer, V.E.; Weinberger, D.M. Relative timing of respiratory syncytial virus epidemics in summer 2021 across the United States was similar to a typical winter season. Influenza Other Respir. Viruses, 2022; epub ahead of print. [CrossRef]

43. Navarro Alonso, J.A.; Bont, L.J.; Bozzola, E.; Herting, E.; Lega, F.; Mader, S.; Nunes, M.C.; Ramilo, O.; Valiotis, G.; Olivier, C.W.; et al. RSV: Perspectives to strengthen the need for protection in all infants. Emerg. Themes Epidemiol. 2021, 18, 15. [CrossRef]

44. Viguria, N.; Martínez-Baz, I.; Moreno-Galarraga, L.; Sierrasesumaga, L.; Salcedo, B.; Castilla, J. Respiratory syncytial virus hospitalization in children in northern Spain. PLoS ONE 2018, 13, e0206474. [CrossRef]

45. Rius-Peris, J.M.; Lucas-Garcia, J.; Garcia-Peris, M.; Tomás, P.E.; Sequi-Canet, J.M.; de Dios, J.G.; ECEALHBA Project Research Group. Consequences of COVID-19 pandemic over acute bronchiolitis hospitalizations in the center and east of Spain. An. Pediatr. 2021, 95, 345–353. [CrossRef]

46. Britton, P.N.; Hu, N.; Saravason, G.; Shrapnel, J.; Davis, J.; Snelling, T.; Dalby-Payne, J.; Kesson, A.M.; Wood, N.; Macartney, K.; et al. COVID-19 public health measures and respiratory syncytial virus. Lancet Child Adolesc. Health 2020, 4, e42–e43. [CrossRef]

47. Savolainen-Kopra, C.; Korpela, T.; Simonen-Tikka, M.L.; Amiryousefi, A.; Ziegler, T.; Roivainen, M.; Hovi, T. Single treatment with ethanol hand rub is ineffective against human rhinovirus–hand washing with soap and water removes the virus efficiently. J. Med. Virol. 2012, 84, 543–547. [CrossRef] [PubMed]

48. Van Summeren, J.J.G.T.; Rizzo, C.; Houveld, M.; Korevaar, J.C.; Hendriksen, J.M.T.; Dückers, M.L.A.; Loconsonde, D.; Chiornna, M.; Bangert, M.; Demont, C.; et al. Evaluation of a standardised protocol to measure the disease burden of respiratory syncytial virus infection in young children in primary care. BMC Infect. Dis. 2021, 21, 705. [CrossRef] [PubMed]

49. World Health Organization. RSV Vaccine Research and Development. Available online: https://www.who.int/immunization/immunization/research/development/ppc_rsv_vaccines/en/ (accessed on 26 December 2021).